BNC105: Interim Phase I data

Interim data from 9 patients with advanced solid tumors in an Australian Phase I trial showed that 2.1-18.9 mg/m 2 IV BNC105 resulted in 2 cases of stable disease. At doses >= 8.4 mg/m 2, DCE-MRI imag...